PL3362094T3 - Kombinacja zawierająca związek tioaminoestrowy lub jego farmaceutycznie dopuszczalną sól oraz związek mogący zwiększyć poziom h2o2 w komórkach nowotworowych osobnika - Google Patents

Kombinacja zawierająca związek tioaminoestrowy lub jego farmaceutycznie dopuszczalną sól oraz związek mogący zwiększyć poziom h2o2 w komórkach nowotworowych osobnika

Info

Publication number
PL3362094T3
PL3362094T3 PL16784442T PL16784442T PL3362094T3 PL 3362094 T3 PL3362094 T3 PL 3362094T3 PL 16784442 T PL16784442 T PL 16784442T PL 16784442 T PL16784442 T PL 16784442T PL 3362094 T3 PL3362094 T3 PL 3362094T3
Authority
PL
Poland
Prior art keywords
combination
thioaminoester
trouble
cells
compound
Prior art date
Application number
PL16784442T
Other languages
English (en)
Polish (pl)
Inventor
Ismail Ceylan
Gerry QUASH
Mileidys PEREZ-ALEA
Guillaume Martin
Original Assignee
Advanced Biodesign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biodesign filed Critical Advanced Biodesign
Publication of PL3362094T3 publication Critical patent/PL3362094T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/131Amines acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4453Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/36Arsenic; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G01N33/57595
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16784442T 2015-10-15 2016-10-14 Kombinacja zawierająca związek tioaminoestrowy lub jego farmaceutycznie dopuszczalną sól oraz związek mogący zwiększyć poziom h2o2 w komórkach nowotworowych osobnika PL3362094T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306650 2015-10-15
EP16784442.2A EP3362094B1 (en) 2015-10-15 2016-10-14 Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject
PCT/EP2016/074682 WO2017064241A1 (en) 2015-10-15 2016-10-14 Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject

Publications (1)

Publication Number Publication Date
PL3362094T3 true PL3362094T3 (pl) 2021-10-11

Family

ID=54360386

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16784442T PL3362094T3 (pl) 2015-10-15 2016-10-14 Kombinacja zawierająca związek tioaminoestrowy lub jego farmaceutycznie dopuszczalną sól oraz związek mogący zwiększyć poziom h2o2 w komórkach nowotworowych osobnika

Country Status (21)

Country Link
US (1) US10406125B2 (enExample)
EP (1) EP3362094B1 (enExample)
JP (1) JP7062592B2 (enExample)
CN (1) CN108348612A (enExample)
AR (1) AR106351A1 (enExample)
CA (1) CA3001201C (enExample)
CY (1) CY1123916T1 (enExample)
DK (1) DK3362094T3 (enExample)
ES (1) ES2870508T3 (enExample)
HR (1) HRP20210358T1 (enExample)
HU (1) HUE054247T2 (enExample)
IL (1) IL258658B (enExample)
LT (1) LT3362094T (enExample)
MX (1) MX377725B (enExample)
PL (1) PL3362094T3 (enExample)
PT (1) PT3362094T (enExample)
RS (1) RS61572B1 (enExample)
SI (1) SI3362094T1 (enExample)
SM (1) SMT202100270T1 (enExample)
WO (1) WO2017064241A1 (enExample)
ZA (1) ZA201802400B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA57224B1 (fr) * 2019-07-31 2022-10-31 Advanced Biodesign Aminothiolesters et leurs utilisations
FR3119314B1 (fr) * 2021-01-29 2025-01-10 Advanced Biodesign Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable
EP4035666A1 (en) * 2021-01-29 2022-08-03 Advanced Biodesign Aminothiolester compound or derivative thereof for use as an immunomodulatory agent
WO2025229179A1 (en) * 2024-05-03 2025-11-06 Advanced Biodesign Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
FR2809727B1 (fr) 2000-05-31 2002-07-26 Galderma Res & Dev Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations

Also Published As

Publication number Publication date
ZA201802400B (en) 2020-01-29
CA3001201C (en) 2023-07-11
IL258658B (en) 2021-04-29
HUE054247T2 (hu) 2021-08-30
BR112018007480A2 (en) 2018-10-23
SI3362094T1 (sl) 2021-04-30
AR106351A1 (es) 2018-01-03
CY1123916T1 (el) 2022-05-27
RS61572B1 (sr) 2021-04-29
JP2018531995A (ja) 2018-11-01
ES2870508T3 (es) 2021-10-27
PT3362094T (pt) 2021-04-15
LT3362094T (lt) 2021-05-10
IL258658A (en) 2018-06-28
EP3362094A1 (en) 2018-08-22
CN108348612A (zh) 2018-07-31
JP7062592B2 (ja) 2022-05-06
WO2017064241A1 (en) 2017-04-20
CA3001201A1 (en) 2017-04-20
EP3362094B1 (en) 2021-02-17
HK1251477A1 (en) 2019-02-01
MX377725B (es) 2025-03-11
US10406125B2 (en) 2019-09-10
DK3362094T3 (da) 2021-03-01
HRP20210358T1 (hr) 2021-04-16
MX2018004381A (es) 2018-05-11
SMT202100270T1 (it) 2021-07-12
US20180303773A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
IL261433A (en) Active data-aware storage manager
GEAP201914688A (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MA47419A (fr) Mousqueton à double verrouillage
IL256455B (en) Phenoxyhalogenphenylamidines and the use thereof as fungicides
PL3322424T3 (pl) Zastosowanie centralnych limfocytów t pamięci przeciwko stronie trzeciej
PL3093361T3 (pl) Element łożyska, stal na element łożyska i sposób ich wytwarzania
HUE060120T2 (hu) Herbicidként aktív 4-difluormetilbenzoilamid
IL272859A (en) Salts of ribociclib and their solid forms
GB2536880B (en) Memory management
GB2536200B (en) Memory management
GB201620954D0 (en) Memory management
GB2537960B (en) Memory management
EP3493489A4 (en) FUSE SAFETY BETWEEN AN ACTIVE PSEUDODRAHT AND A STANDBY PSEUDO WIRE
ZA201901543B (en) Heterocyclic compound, and harmful-arthropod-controlling agent containing same
IL256722B (en) Self belay arrangement for climbing applications
PL3362094T3 (pl) Kombinacja zawierająca związek tioaminoestrowy lub jego farmaceutycznie dopuszczalną sól oraz związek mogący zwiększyć poziom h2o2 w komórkach nowotworowych osobnika
GB2536199B (en) Memory management
MA47569A (fr) Composé guanidine et bactéricide
PL3231417T3 (pl) Odporna na składowanie kompozycja oftalmiczna
EP3357634A4 (en) WORKING CENTER
PL3338929T3 (pl) Płytka skrawająca
DK3522424T3 (da) Soft-buffer-håndtering med begrænset hukommelsesadgangsbåndbredde
JP2017012034A5 (enExample)
EP3616067A4 (en) MEMORY FORMS
AU201713377S (en) Storage can